Eventide Asset Management Review

Company History and Founding Vision

Eventide Asset Management was founded in 2008 in Boston, Massachusetts, by Finny Kuruvilla, who serves as Co-Chief Investment Officer and Senior Portfolio Manager. Kuruvilla’s background is unusual in the investment world: he holds an MD from Harvard Medical School, a PhD in chemistry from Harvard, and previously worked in venture capital at Clarus Ventures, where he focused on healthcare and life sciences investments. This combination of scientific rigor and medical ethics would come to define Eventide’s approach to faith-based investing.

The founding vision grew from Kuruvilla’s conviction that investing should do more than avoid harm—it should actively promote human flourishing. Where most faith-based investment firms at the time focused primarily on screening out companies involved in alcohol, tobacco, gambling, and other “sin stock” categories, Kuruvilla envisioned a more comprehensive framework that would evaluate companies holistically: not just what they avoid, but what they actively contribute to the world. This vision became the foundation for Eventide’s Business 360 methodology.

From its founding during the 2008 financial crisis, Eventide has grown into a significant force in faith-based investing, reaching $6.4 billion in assets under management as of mid-2025. The firm operates as an employee-owned company, with more than 20 of its 74 employees holding equity stakes—a structure that aligns the interests of the team with the long-term success of investors. Eventide has been named one of the Best Places to Work in Money Management by Pensions & Investments for five consecutive years, and maintains a 5.0 Glassdoor rating for culture and values, suggesting that the firm’s mission-driven identity extends beyond marketing into genuine corporate culture.

Eventide’s mission statement—”investing that makes the world rejoice”—captures an ambitious vision that positions the firm not merely as a financial services provider but as an organization seeking to align capital with God’s purposes for creation. This dual identity as both investment manager and ministry shapes the firm’s product design, research methodology, and public engagement through initiatives like the Eventide Center for Faith and Investing.

The Business 360 Methodology: How Eventide Evaluates Companies

At the heart of Eventide’s investment approach is the proprietary Business 360 framework, which represents one of the most sophisticated evaluation methodologies in the faith-based investing space. Understanding Business 360 is essential for any investor considering Eventide’s funds, because it fundamentally shapes what companies end up in the portfolio—and why.

Business 360 evaluates companies through two complementary lenses: what a company makes (its products and services) and how it makes it (its business practices and stakeholder relationships). This dual analysis distinguishes Eventide from providers that focus primarily on negative screening—simply excluding companies in objectionable industries.

The methodology works in two stages. The first stage involves quantitative screening, where Eventide processes over 170 million data points from external data vendors and internal web scraping to evaluate companies across more than 50 ethical dimensions. This automated screening identifies companies with involvement in abortion (including abortifacient drugs, abortion facilities, and fetal tissue research), pornography and adult entertainment, gambling operations, alcohol production, tobacco manufacturing, and human rights violations including child labor and forced labor. Companies flagged in these categories are excluded from consideration.

The second stage is where Business 360 truly differentiates itself: a qualitative, human-driven research process in which Eventide’s analysts conduct deep-dive evaluations of companies that pass the initial screens. This research assesses whether a company’s products and practices create genuine value for all stakeholders—employees, customers, suppliers, communities, and shareholders. Companies are evaluated not just on the absence of harm but on the presence of positive contribution to human flourishing. Factors include ethical corporate governance, community investment and charitable engagement, environmental stewardship, fair labor practices, family-friendly workplace policies, and the extent to which the company’s core products and services contribute meaningfully to society.

This approach reflects Eventide’s theological conviction that creation itself is good—that business, properly conducted, is a vehicle for blessing rather than merely a morally neutral activity to be screened for contamination. The result is a portfolio construction methodology that seeks companies actively making the world better, not just companies that aren’t making it worse.

The Avoid-Embrace-Engage Framework

Eventide organizes its investment philosophy around three complementary strategies: Avoid, Embrace, and Engage. This framework provides a practical structure for how the Business 360 methodology translates into actual portfolio decisions.

The “Avoid” component is the most straightforward: Eventide excludes companies that siphon value from stakeholders rather than creating it. This includes companies in the traditional “sin stock” categories (abortion, pornography, tobacco, alcohol, gambling) as well as companies engaged in exploitative labor practices, environmental destruction, or other activities that harm human flourishing. Unlike some faith-based providers that apply narrow screens, Eventide’s avoidance criteria extend to the broader question of whether a company’s fundamental business model creates or destroys value for the people it touches.

The “Embrace” component is where Eventide most clearly differentiates itself. Rather than simply investing in whatever passes the negative screens, Eventide actively seeks out companies that demonstrate exceptional value creation for all stakeholders. These are companies whose products solve real problems, whose employment practices dignify workers, whose supply chain relationships are fair and sustainable, and whose overall impact on the world is demonstrably positive. The embrace framework shifts the investment question from “what should we avoid?” to “what should we actively support?”—a fundamentally different orientation than traditional exclusionary screening.

The “Engage” component involves using Eventide’s position as a shareholder to influence companies toward better practices. Through shareholder advocacy, proxy voting, and direct engagement with management teams, Eventide works to improve the behavior of companies it holds. This approach acknowledges that few companies are perfect, and that ownership carries not just financial benefits but also responsibility and influence. Eventide publishes proxy voting records and engagement activities, allowing investors to see how the firm exercises its ownership responsibilities.

Complete Fund Lineup

Eventide offers one of the most comprehensive fund lineups in the faith-based space, spanning U.S. equity (large-cap through small-cap), international equity, sector-specific strategies, fixed income, balanced allocation, and increasingly, exchange-traded funds. Here is a detailed overview of each offering.

Eventide Gilead Fund (ETGLX/ETILX). This is Eventide’s flagship fund and the one most investors associate with the firm. With approximately $2.89 billion in assets, the Gilead Fund is classified as a mid-cap growth fund and represents the purest expression of the Business 360 methodology. The fund seeks companies that are creating compelling value for customers, employees, and society while maintaining strong competitive positions. Performance has been strong over longer periods: the fund returned 22.76% in 2023 and approximately 11.64% in 2025, though 2024 was essentially flat at -0.02%. The one-year return through early 2026 stands at approximately 21.4%, with a three-year annualized return of 10.2%. Expense ratios are 1.38% for the institutional class (ETILX), which is typical for actively managed faith-based funds but significantly higher than passive alternatives. Available share classes include Institutional (ETILX), Class N (ETGLX), Class C (ETCGX), and Class A (ETADX).

Eventide Healthcare & Life Sciences Fund (ETIHX/ETAHX). This sector-specific fund leverages Kuruvilla’s medical and scientific background, focusing on healthcare and biotechnology companies that advance human health. The fund invests in companies developing innovative therapies, medical devices, and healthcare services, screened through the Business 360 lens for ethical practices. Performance has been notably volatile—characteristic of biotech investing—but the one-year return through early 2026 was an impressive 44.8%, with a three-year annualized return of 13.7%. The five-year annualized return of -0.7% reflects the sharp drawdowns that biotech portfolios experienced during the 2022 growth stock selloff. Expense ratios range from 1.32% (institutional) to 2.32% depending on share class. This fund is best suited for investors who understand healthcare sector volatility and want exposure to medical innovation through a faith-based lens.

Eventide Large Cap Focus Fund (ETLCX/ETLIX). Launched in 2022, this newer addition to the lineup targets S&P 500-sized companies, providing large-cap exposure with active management and Business 360 screening. With an expense ratio of 1.19% for the institutional class, it represents Eventide’s entry into the large-cap space where it competes more directly with index-oriented offerings from providers like Inspire (PTL at 0.09%) and GuideStone‘s Equity Index Fund. The higher fee reflects Eventide’s active management approach, which aims to add value through security selection rather than simply replicating a screened index.

Eventide Dividend Growth Fund (ETIDX). This fund focuses on companies with strong and growing dividend payments, screened through the Business 360 methodology. The dividend growth approach appeals to investors seeking income and lower volatility alongside faith-based screening. The fund won a Refinitiv Lipper Award as Best Equity Income Fund Over 3 Years in 2022, validating Eventide’s ability to deliver competitive income-oriented performance within a values-based framework.

Eventide Exponential Technologies Fund (ETIEX). This fund targets technology and innovation companies with the potential for exponential growth—companies developing breakthrough solutions in areas like artificial intelligence, cloud computing, cybersecurity, and digital health. Expense ratios range from 1.68% to 2.43% depending on share class, making it one of Eventide’s more expensive offerings. The fund appeals to growth-oriented investors who want exposure to technological innovation without holding companies whose technologies are deployed in ways that conflict with their values.

Eventide Balanced Fund (ETIMX). For investors who prefer a single-fund solution, the Balanced Fund maintains an approximately equal split between equity and fixed income holdings, all screened through Business 360. With an expense ratio of 1.82%, it provides built-in diversification and automatic rebalancing, making it suitable for investors who want a complete, values-aligned portfolio in one fund without the complexity of managing multiple holdings.

Eventide Multi-Asset Income Fund. This fund focuses on generating income from a diversified mix of dividend-paying stocks, bonds, and other income-producing investments, all screened for biblical alignment. With an expense ratio of approximately 1.02%, it is among Eventide’s more cost-competitive mutual fund offerings and serves investors who prioritize current income alongside values-based investing.

Eventide Core Bond Fund (ETIRX) and Limited-Term Bond Fund (ETIBX). Eventide’s fixed income offerings provide bond exposure with faith-based screening applied to corporate bond issuers. The Core Bond Fund carries an expense ratio of 0.48-0.58%, while the Limited-Term Bond Fund runs 0.45-0.55%—both significantly lower than Eventide’s equity fund fees and competitive with other faith-based bond offerings. These funds serve the conservative allocation portion of a diversified portfolio.

Eventide’s ETF Expansion

Recognizing the growing investor preference for ETF structures, Eventide launched its first exchange-traded funds in 2024 and has been rapidly expanding the lineup. This represents a strategic shift for a firm that built its reputation on actively managed mutual funds.

Eventide U.S. Market ETF (ESUM). Originally launched under the ticker EUSM, this ETF changed its ticker to ESUM in September 2025. With approximately $129 million in assets and a 0.39% expense ratio, ESUM provides broad U.S. equity exposure with Business 360 screening. While more expensive than Inspire’s PTL (0.09%), the ETF reflects Eventide’s more comprehensive screening approach and active management.

Eventide High Dividend ETF (ELCV). Launched in September 2024, ELCV has quickly attracted approximately $155 million in assets. With a 0.49% expense ratio, the fund targets high-dividend-paying U.S. companies that meet Eventide’s ethical standards, providing income-focused investors with an ETF alternative to the Dividend Growth mutual fund.

Systematic ETF Series (ESLG, ESLV, ESSC). In September 2025, Eventide launched three new systematic ETFs covering Large Cap Growth (ESLG), Large Cap Value (ESLV), and Small Cap (ESSC). These ETFs use quantitative, rules-based strategies alongside Business 360 screening, representing Eventide’s move toward lower-cost, more scalable investment products that complement its traditional actively managed offerings.

Eventide International ETF (ESIM). Approved for launch in late 2025, ESIM extends Eventide’s ETF lineup into international markets, providing non-U.S. equity exposure with faith-based screening. This fills a gap in Eventide’s offerings and competes with Inspire’s WWJD international ETF.

The ETF expansion signals an important evolution in Eventide’s strategy. While the firm’s intellectual identity is rooted in the deep, qualitative research of Business 360, the ETF format allows Eventide to reach cost-conscious investors who might not be willing to pay mutual fund-level expense ratios. The systematic ETFs in particular represent a bridge between Eventide’s values-driven approach and the lower-cost, rules-based investing that has dominated the broader market.

GoodInvestor.com: Free Screening Tool

In August 2024, Eventide launched GoodInvestor.com, a free online tool that allows any investor to screen mutual funds, ETFs, and publicly traded companies for ethical concerns across five categories: abortion, alcohol, gambling, pornography, and tobacco. The tool draws on Eventide’s 17 years of Business 360 research to provide accessible screening data that was previously available only to institutional investors.

GoodInvestor represents an interesting strategic move. By making its screening data freely available, Eventide positions itself as a thought leader and educational resource for the broader faith-based investing community—not just a fund provider. Investors can use the tool to evaluate their existing portfolios for ethical exposure, which may lead them to consider Eventide’s products as alternatives. The tool also includes educational research reports on each ethical issue, documenting how industries like tobacco and gambling profit from addiction and exploitation.

For investors who are just beginning to explore faith-based investing, GoodInvestor provides a low-barrier entry point: check your current mutual funds and ETFs for hidden ethical exposure, learn about the issues, and make more informed decisions about whether to reallocate. This aligns with Eventide’s broader educational mission through the Eventide Center for Faith and Investing.

The Eventide Center for Faith and Investing

Established in 2021, the Eventide Center for Faith and Investing serves as the firm’s educational and thought leadership platform. The Center publishes The Journal for Faith and Investing, produces the Faith and Investing Podcast, offers educational courses for both individual investors and financial advisors, and curates resources on the intersection of Christian faith and investment practice.

This initiative reflects Eventide’s conviction that the faith-based investing conversation needs to go deeper than product marketing. The Center addresses foundational questions about what the Bible teaches about business, wealth, stewardship, and the proper role of financial markets in a just society. For investors evaluating Eventide, the Center’s resources provide insight into the theological and philosophical foundations that drive the firm’s investment decisions.

Private Investments: Healthcare Innovation

Beyond publicly traded securities, Eventide operates a private investment arm focused on healthcare innovation. The Eventide Healthcare Innovation Fund I completed its final close in May 2024, raising $83 million from endowments, foundations, and family offices. The fund invests in early to late-stage biotechnology companies developing innovative treatments for underserved patient populations—a direct expression of Kuruvilla’s medical background and Eventide’s mission to invest in human flourishing.

Eventide’s private investment track record includes over $500 million invested in 38 private healthcare and biotech companies. While private funds are available only to accredited and institutional investors, they demonstrate the depth of Eventide’s healthcare and life sciences expertise—expertise that also informs the public Healthcare & Life Sciences Fund.

Advisory Services and Separately Managed Accounts

Eventide offers separately managed accounts (SMAs) on both discretionary and non-discretionary bases. Available strategies include Large Cap Core, U.S. Market Equity, Dividend Value, Technology, and Small Cap—each applying the Business 360 methodology to individually managed portfolios. As of December 2024, Eventide managed $6.4 billion in discretionary assets and approximately $142 million in non-discretionary advisory assets.

SMAs are primarily available through financial advisors and intermediary platforms rather than directly to individual retail investors. For high-net-worth individuals, families, endowments, and foundations seeking customized, values-aligned portfolio management, Eventide’s SMA strategies provide an alternative to the one-size-fits-all structure of mutual funds and ETFs.

Strengths and Advantages

Intellectual depth and rigor. Eventide’s Business 360 methodology is arguably the most intellectually rigorous approach in the faith-based investing space. The combination of quantitative data processing (170+ million data points) and qualitative human research produces a more nuanced evaluation than simple exclusionary screening. Where other providers ask “is this company in a bad industry?”, Eventide asks the deeper question: “is this company creating genuine value for all its stakeholders?”

Beyond avoidance to active embrace. The Avoid-Embrace-Engage framework represents a philosophical advance in faith-based investing. By actively seeking companies that contribute to human flourishing—rather than merely excluding companies in objectionable industries—Eventide offers a positive investment thesis that resonates with investors who believe business itself can be a force for good in the world.

Sector expertise in healthcare. Kuruvilla’s medical and scientific background gives Eventide a genuine competitive advantage in healthcare and biotech investing. The Healthcare & Life Sciences Fund and the private healthcare innovation fund leverage deep domain expertise that most investment firms—faith-based or otherwise—simply don’t possess.

Shareholder engagement. Eventide’s commitment to active shareholder engagement adds a dimension that passive index providers cannot offer. By voting proxies and engaging directly with management teams, Eventide uses its ownership position to influence corporate behavior—putting faith-based principles into practice at the governance level.

Growing ETF lineup. The expansion into ETFs addresses one of Eventide’s historical weaknesses (high fees on mutual funds only) by providing lower-cost, more accessible options. Investors can now access Eventide’s screening methodology through ETFs with expense ratios starting at 0.39%.

Employee ownership and culture. The employee-owned structure and consistently high workplace ratings suggest a firm where mission and culture are genuine, not just marketing. Five consecutive years on Pensions & Investments’ Best Places to Work list is a meaningful signal of organizational health.

Limitations and Considerations

Higher expense ratios on mutual funds. Eventide’s mutual fund fees remain among the highest in the faith-based space. The flagship Gilead Fund at 1.38% costs more than fifteen times what Inspire charges for its PTL ETF (0.09%). While active management can justify higher fees when it delivers superior returns, cost-conscious investors—particularly those in tax-advantaged retirement accounts where the tax efficiency of ETFs is irrelevant—should carefully consider whether Eventide’s active management adds enough value to justify the fee premium. The newer ETFs (0.39-0.49%) help address this concern but remain more expensive than Inspire’s most competitive offerings.

Key-person risk. Morningstar has specifically flagged Eventide’s concentration of intellectual capital in Finny Kuruvilla as a risk factor. As the firm’s co-founder, Co-Chief Investment Officer, and the architect of the Business 360 methodology, Kuruvilla is deeply integrated into Eventide’s investment process and identity. While the firm has been building out its team—including hiring I-hung Shih in 2024 to co-manage the Healthcare & Life Sciences strategy—Kuruvilla’s centrality to the firm’s approach and reputation represents a meaningful succession and continuity risk.

Performance volatility. Eventide’s active, conviction-driven approach produces more performance variability than index-tracking alternatives. The Healthcare & Life Sciences Fund exemplifies this: an impressive 44.8% one-year return but a -0.7% five-year annualized return through early 2026. The Gilead Fund’s near-zero 2024 return (-0.02%) following strong 2023 performance (22.76%) illustrates how active stock selection can produce uneven year-to-year results. Investors need a long time horizon and tolerance for short-term underperformance.

Subjectivity in Business 360. While Eventide’s methodology is more comprehensive than simple exclusionary screening, it is also inherently more subjective. Different analysts may reach different conclusions about whether a company is creating genuine value for all stakeholders. The qualitative judgment involved in the “embrace” and “engage” components introduces human interpretation that some investors may find less transparent or reproducible than rules-based screening approaches.

Mutual fund structure for core offerings. Despite the ETF expansion, Eventide’s most established and well-known funds—including the Gilead Fund and Healthcare & Life Sciences Fund—remain available only as mutual funds. For investors in taxable accounts, this means potentially less tax efficiency compared to ETF alternatives from other faith-based providers. In tax-advantaged retirement accounts, this distinction matters less.

Morningstar parent rating. Morningstar assigns Eventide an “Average” parent rating—acknowledging the firm’s mission-driven approach but citing elevated key-person risk and high fees as concerns. While Morningstar ratings reflect backward-looking analysis and don’t predict future performance, this assessment from a respected independent evaluator deserves consideration.

Who Should Consider Eventide

Eventide is well-suited for Christian investors who want their investments to actively promote human flourishing rather than simply avoiding harmful industries, investors who value deep research and are willing to pay higher fees for active management with faith-based conviction, healthcare and biotech-focused investors who want sector expertise combined with ethical screening, long-term investors with the patience to tolerate short-term performance variability in exchange for a distinctive investment approach, advisors and institutions seeking sophisticated, values-aligned strategies with a strong intellectual foundation, and investors who appreciate shareholder engagement and want their fund manager to actively advocate for ethical corporate behavior.

Eventide may not be the best fit for cost-focused investors who prioritize the lowest possible expense ratios (consider Inspire’s PTL ETF at 0.09%), passive index investors who prefer rules-based screening with minimal tracking error, investors uncomfortable with performance volatility and year-to-year variability, those seeking denomination-specific screening aligned with Catholic teaching (consider Ave Maria Funds), investors who want integrated retirement plan services alongside their investments (consider GuideStone), or investors who prefer complete transparency in screening rules with the ability to look up individual company scores (consider Inspire’s Impact Score tool).

Eventide vs. Other Faith-Based Providers

Understanding how Eventide compares to other major faith-based investment providers helps investors choose the approach that best fits their priorities.

Compared to Inspire Investing, Eventide offers a more research-intensive, actively managed approach at higher cost. Inspire excels at low-cost, passive ETF investing with transparent scoring (the Inspire Impact Score), while Eventide excels at deep, qualitative company analysis and active portfolio management. Notably, there is virtually zero overlap in the top holdings between comparable funds from each provider—illustrating how different screening methodologies can produce very different portfolios even within the same faith-based investing space. Cost-conscious passive investors lean toward Inspire; conviction-driven active investors lean toward Eventide.

Compared to GuideStone Funds, Eventide offers deeper screening methodology but lacks GuideStone’s comprehensive retirement plan infrastructure, Ministers’ Housing Allowance support, and integrated insurance products. GuideStone’s screening is more conservative (excluding only about 15 S&P 500 companies), while Eventide’s Business 360 approach is more holistic and may exclude—or include—different companies based on its broader evaluation criteria. Ministry workers and church organizations with retirement plan needs are better served by GuideStone; individual investors seeking the most thoughtful screening approach may prefer Eventide.

Compared to Timothy Plan, which pioneered faith-based mutual fund investing, Eventide offers a more comprehensive evaluation methodology. Timothy Plan applies broader exclusionary screens but doesn’t emphasize the positive “embrace” and “engage” components that define Eventide’s approach. Investors who want the strictest possible exclusionary screening may prefer Timothy Plan; those who value positive selection and shareholder engagement lean toward Eventide.

The Bottom Line

Eventide Asset Management stands apart in the faith-based investing landscape through its commitment to intellectual rigor, its holistic Business 360 methodology, and its conviction that investing should actively promote human flourishing rather than merely avoid harm. The firm’s unusual founding story—a Harvard-trained physician applying scientific discipline to faith-based investment analysis—has produced an approach that takes both the “faith” and the “investing” in faith-based investing seriously.

The trade-offs are real: higher fees, more performance volatility, key-person risk, and the inherent subjectivity of qualitative company evaluation. Eventide is not the right choice for every Christian investor. Cost-conscious indexers, retirement plan participants, and investors who prefer transparent rules-based screening may find better fits elsewhere.

But for investors who believe that the question “what does this company contribute to the world?” is as important as “what does this company avoid?”—and who are willing to pay for deep research and active management to pursue that conviction—Eventide offers something genuinely distinctive. The growing ETF lineup makes the firm’s approach more accessible than ever, and the GoodInvestor screening tool demonstrates a commitment to serving the broader faith-based investing community beyond just its own fund shareholders.

As with all investment decisions, Eventide’s products should be evaluated within the context of your complete stewardship strategy—including budgeting, debt management, generous giving, and a prayerful approach to managing the resources God has entrusted to you. The best investment strategy is one that aligns your money with your deepest convictions while prudently building for the future—and Eventide provides one compelling framework for doing exactly that.